by American Association for Cancer Research Remetinostat, a topical cream and first-in-class inhibitor of histone deacetylation showed signs of clinical efficacy in patients with basal cell carcinoma, according to results from a phase II clinical trial published in Clinical Cancer Research. Basal cell carcinoma (BCC) is the most common form of skin cancer and is typically treated...